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Abstract – Rift Valley fever (RVF) virus is an arbovirus in the Bunyaviridae family that, from phylogenetic
analysis, appears to have ﬁrst emerged in the mid-19th century and was only identiﬁed at the begininning of
the 1930s in the Rift Valley region of Kenya. Despite being an arbovirus with a relatively simple but
temporally and geographically stable genome, this zoonotic virus has already demonstrated a real capacity
for emerging in new territories, as exempliﬁed by the outbreaks in Egypt (1977), Western Africa (1988) and
the Arabian Peninsula (2000), or for re-emerging after long periods of silence as observed very recently in
Kenya and South Africa. The presence of competent vectors in countries previously free of RVF, the high
viral titres in viraemic animals and the global changes in climate, travel and trade all contribute to make this
virus a threat that must not be neglected as the consequences of RVF are dramatic, both for human and
animal health. In this review, we present the latest advances in RVF virus research. In spite of this renewed
interest, aspects of the epidemiology of RVF virus are still not fully understood and safe, effective vaccines
are still not freely available for protecting humans and livestock against the dramatic consequences of this
virus.
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1. INTRODUCTION
Rift Valley fever virus (RVFV; Bunyaviri-
dae: Phlebovirus) is primarily transmitted by
mosquitoes and causes a potentially severe dis-
ease among both humans and animals. The
virus was ﬁrst identiﬁed in 1930, during an out-
break of sudden deaths and abortions among
sheep along the shores of Lake Naivasha in
the greater Rift Valley of Kenya [51, 52]. The
geographic distribution of the virus has since
grown signiﬁcantly and now includes most
countries of the African continent and
Madagascar [100]. It emerged for the ﬁrst time
outside Africa in the Arabian Peninsula in
2000–2001 and caused a large outbreak in live-
stock and humans [11]. More recently, it was
detected for the ﬁrst time in the Archipelago
of Comores, located between Mozambique
and Madagascar, on the French Island of
Mayotte [242]. Due to the increasing range of
the virus, the high numbers of competent vector
species present in currently RVF-free regions,
such as Europe [199] and the USA [95, 266],
the intensiﬁcation of international trade in live
animals, and the unknown impact of climate
change, several national and international agen-
cies have issued warnings about the heightened
risk of introduction of RVFV into RVF-free
countries [27, 37, 57, 69, 92, 140, 170, 224,
229, 280, 291]. These reports conclude unani-
mously that coordinated efforts to better prepare
for a possible emergence of RVFV are
needed.
This review provides a comprehensive
update on RVFV, with particular attention
devoted to the molecular epidemiology, virus
genetics, vectors, diagnostic techniques and
the pathogenesis of this signiﬁcant veterinary
and public health threat [22, 26, 85,
100, 253].
2. GENETIC ORGANIZATION
OF THE RVFV
Like all bunyaviruses, RVFV is an envel-
oped RNA virus characterized by a genome
composed of three segments designated L, M
and S of negative or ambisense polarity. All
the replication steps occur in the cytoplasm of
infected cells and virions mature by budding
in the Golgi compartment [207].
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2.1.1. The virion
Early ultrastructural studies by electron
microscopy and negative staining described
RVFV particles measuring 90–110 nm in diam-
eter [77]. The envelope is composed of a lipid
bilayer containing the Gn and Gc glycoproteins
forming surface sub-units, 5–8 nm in length,
regularly arranged on its surface, similar to
those reported for the related Uukuniemi
phlebovirus [273]. The viral ribonucleoproteins
(RNP) corresponding to each of the three geno-
mic segments, associated with numerous copies
of the nucleoprotein N and the RNA dependent
RNA polymerase L, are packaged into the
virion. More recent studies by cryo-electron
microscopy on Uukuniemi virus and RVFV
have modiﬁed the former view that phlebovi-
ruses are pleiomorphic [89, 118, 212, 238].
Instead these studies indicated that virions are
likely to have an icosahedral symmetry: the
structure is highly ordered and the surface cov-
ered by a shell of 120–122 glycoprotein cap-
somers arranged in an icosahedral lattice with
T = 12. Three dimensional reconstructions at
22 or 27 A ˚ resolution revealed that the capsom-
ers resemble hollow cylinders situated at ﬁve-
and six-coordinated positions. Inside the
envelope, a layer of RNP is located proximal
to the inner leaﬂet of the membrane, strongly
suggesting an interaction between the cytosolic
tail of the glycoproteins and the RNP which
would compensate for the absence of matrix
protein in the viruses of this family.
2.1.2. The viral genome
The RVFV genome is composed of three
segments, L, M and S, which are presumed to
be packaged together in the virions in the form
of RNP. Sequencing indicated that the 30 and 50
terminal sequences are complementary to each
other, forming panhandle structures, and
explains the ﬁnding that RNP are circular when
observed by electron microscopy [75]. The L
and M segments are of negative polarity, coding
respectively for the L protein, which is the viral
RNA-dependent RNA polymerase [200], and
for the precursor to the glycoproteins [46, 47].
The S segment utilizes the ambisense strategy
to code for two proteins, the nucleoprotein N
and a nonstructural protein called NSs [104].
The coding capacity of the genome is depicted
in Figure 1. The general view that only the viral
genome is incorporated into the mature particle
has been revisited since a small but signiﬁcant
fraction of the antigenomes i.e. replicative inter-
mediates have been detected in puriﬁed RVFV
particles [123]. These data correlate with past
studies on Uukuniemi virus showing that the
S segment of genomic and antigenomic
polarities could be detected in puriﬁed virions
[241].
2.2. The viral replication cycle: role and
function of viral genes and their products
2.2.1. Transcription and replication
The general features of RVFV transcription
and replication are similar to those of other neg-
ative stranded RNAviruses [74, 75]. During the
replication cycle, each segment is transcribed
into mRNA and is replicated through a process
which involves the synthesis of the exact copy
of the genome, called complementary RNA
(cRNA) or antigenome. For phleboviruses,
and RVFV in particular, the cRNA representing
the copy of the S ambisense segment serves as a
template for the synthesis of the NSs mRNA.
Since the S cRNA is present in the input virus,
the protein is expressed early, a good indication
that it has an important role during infection.
Messenger RNA synthesis is initiated through
a cap-snatching mechanism whereas the synthe-
s i so fc R N Ai si n i t i a t e dw i t h5 0 nucleoside
triphosphates. Furthermore, cRNA is the com-
plete copy of the vRNAwhereas mRNAs termi-
nate in the non-coding region before the 50 end
of the template for the L and M segments or
in the intergenic region for the S segment.
The switch between the two activities of the
L polymerase remains unknown; although sev-
eral polymerase consensus motifs were found in
the L protein [200], the different domains of the
L protein responsible for the activities of cap-
snatching or transcription termination have not
been determined yet.
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and allow for the rescue of infectious viruses
from cDNA have now been established by sev-
eral different groups [17, 103, 107, 124].
Besides being an essential step in the develop-
ment of reverse genetics, minigenomes mimick-
ing a genome segment in which the viral ORF
is replaced by a reporter gene have been helpful
to analyze various steps in RNA synthesis, i.e.
transcription, replication, transcription termina-
tion and packaging. Minigenomes can be
expressed from T7 or PolI promoter-based plas-
mids. Expression under the control of the T7
promoter requires transfection in cells express-
ing the T7 RNA polymerase such as the
BSR-T7/5 [48] or BHK/T7-9 cells [129]
whereas expression from the PolI promoter is
species speciﬁc so that the cells used for the
study must correspond to the species of the pro-
moter sequence [205]. Studies with minige-
nomes clearly established that transcription
and replication of the viral-like RNA requires
the expression of the N and L proteins, which
are necessary to reconstitute RNP, thus conﬁrm-
ing the concept [161] that naked RNA cannot
be transcribed. These data also indicate that L
protein by itself or in association with N is able
to assume both transcription and replication,
excluding the possibility that the L protein
had to be modiﬁed by a viral factor to function
as a replicase. One should note however, that
the RVFV NSs was reported to promote viral
RNA replication and transcription in a minige-
nome system [122] but this particular character-
istic was not conﬁrmed
1; instead, RVFV NSs
was found to be inhibitory, like the NSs of
the related Bunyamwera virus [281]. This
difference may be due to the experimental
conditions utilized by the two groups: RVFV
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Figure 1. Schematic diagram of Rift Valley Fever virus (electron micrograph from Linda Stannard [258]).
(A color version of this ﬁgure is available online at www.vetres.org.)
1 Bouloy M., unpublished data.
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transcript in 293 versus BSR cells.
When compared to each other, the L, M and
S segment-based minigenomes do not express
identical levels of reporter gene, indicating dif-
ferential promoter activities associated with the
non-coding regions [97]. Although the muta-
genesis was not as extensive as the one carried
out for Uukuniemi virus [84], it appeared that
some of the conserved nucleotides in the non-
coding regions, particularly the ﬁrst 8 terminal
nucleotides and the purine at position 13, play
an important role in promoter activity and the
regulation of gene expression [226].
In contrast with most viral or cellular
mRNA, bunyavirus mRNA are not polyadeny-
lated. The M segment derived mRNA of the
Sin Nombre hantavirus seems to be the only
exception reported to date [120]. The bunyavi-
ral mRNA terminate prematurely on their tem-
plate, strongly suggesting that the transcriptases
recognize a transcription termination signal.
Preliminary data suggested that a conserved
motif is present in the intergenic region of the
S segment of Toscana, sandﬂy fever Sicilian
and RVF viruses [104, 106], contrasting with
other ambisense viruses where RNA hairpin
structures serve as termination signals [162].
To further understand the termination process,
Albarino et al. [3] mapped precisely the 30
end of the 4 RVFV mRNA: N mRNA, NSs
mRNA and the M- and L-derived mRNA,
and identiﬁed a conserved sequence motif
‘‘30-C1–3GUCG/A’’ on both M and ambisense
S segment sequences of several phleboviruses
of the sandﬂy serogroup. To demonstrate the
role of this sequence, they created a recombi-
nant RVFV lacking the termination motif in
the S segment by reverse genetics. Analysis
of the mRNA synthesized in the cells infected
with this mutated virus showed that the trans-
criptase failed to terminate the S mRNA cor-
rectly. Using a method of RNase protection
assays to map the 30 end, Ikegami et al. [125]
came to a similar conclusion on the termination
of the S and M segments. However, the two
reports presented conﬂicting data on the L seg-
ment, which lacks the pentanucleotide motif in
the 50 non-coding region. Albarino et al. [3]
reported that L mRNA represents the complete
copy of its template whereas Ikegami et al.
[125] claimed that the L mRNA lacks the last
16–41 nucleotides when compared to the full-
length cRNA copy and that the termination
signal corresponds to two 13-nucleotide-long
complementary sequences present in the 50
non-coding region of the L genomic segment.
2.2.2. The glycoproteins and their role in cell
entry and particle formation
During the viral cycle, the glycoproteins
play an essential role for the penetration of
the virus and their proper processing is crucial
for the maturation and budding of the virion.
The glycoproteins, being the most exposed
components of the virus during infection, are
recognized by the immune system and induce
the production of neutralizing antibodies, which
play a predominant role in protection. The gly-
coproteins also mediate virus entry into many
cell types through speciﬁc receptors which, in
the case of RVFV and many other bunyavirus-
es, remain to be identiﬁed. Entry is predicted
to employ a class II fusion mechanism that is
activated by low pH following endocytosis of
the virion [82]. Little is yet known regarding
the early phases of infection that precede the
release of virus RNP into the cytosol.
The RVFV M segment codes for a polypro-
tein precursor which, after cleavage, generates
Gn (encoded by amino-terminal sequences of
the precursor) and Gc (encoded by carboxy-
terminal sequences) as well as two nonstruc-
tural proteins, the 78 kDa (also called NSm1)
and the 14 kDa (NSm2) proteins. The question
was raised of whether the 78 kDa protein is a
structural protein [227], but a more recent work
indicated that this protein was not detected in
puriﬁed particles [89]. The NSm1 and NSm2
nonstructural proteins are produced by
alternative use of the ﬁrst or the second of the
5 in-frame AUG codons present at the 50 end
of the M mRNA and located upstream of the
Gn sequence (Fig. 2). The ﬁrst AUG initiates
the synthesis of the 78 kDa NSm1 product
which includes the sequence of Gn while the
second AUG is utilized for the synthesis of
the 14 kDa NSm2 which terminates before
Gn. The ﬁrst and fourth AUG precede
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ing that NSm1 and Gn could be directed to the
endoplasmic reticulum (ER). Wasmoen et al.
[278] showed that, regardless of the presence
of NSm1 and NSm2, Gn and Gc are localized
in the Golgi complex, suggesting that the sig-
nals for Golgi localization reside in Gn and/or
Gc. However, when expressed in the absence
of Gn,G c localizes to the ER due to the pres-
ence of a lysine-based ER retrieval signal at
its C terminus [101]. This suggests that Gc
moves to the Golgi apparatus via its physical
association with Gn. Localization of the glyco-
proteins in the Golgi complex is essential for
proper maturation of the bunyavirus particles
which bud into the lumen of the Golgi.
RVFV-infected hepatocytes seem to represent
the only known exception as budding of parti-
cles was observed to occur at the plasma mem-
brane as well as at the Golgi vesicles [5]. Late
in infection, in most vertebrate cells, the Golgi
complex undergoes morphological changes,
with vacuolization and dispersion of small and
large vesicles in the cytoplasm. Virions are then
transported within these vacuoles to the cell
surface where fusion of the vacuole and plasma
membranes allows for the release of virus into
the extracellular medium.
Minigenome systems, developed to assess
transcription and replication activity, were also
used to evaluate packaging activity. The glyco-
proteins, which are co-expressed together with
the transcription machinery, allow formation
of the viral like particles (VLP) which are
released into the medium [108]. When observed
by electron microscopy and negative staining,
these particles resemble RVFV particles in size
and morphology. They were able to infect naı ¨ve
cells and to undergo the ﬁrst step of the replica-
tion cycle, i.e., primary transcription. If both L
and N are provided in trans, replication of mi-
nigenomes occur [204]. Interestingly, similar
RVFV VLP were produced in insect cells
infected with a dual baculovirus vector express-
ing Gn/Gc glycoproteins and the N protein.
Another vector expressing N and only Gc was
constructed but was found to produce particles
of a more pleiomorphic nature, suggesting that
both Gn and Gc contribute to the assembly pro-
cess and likely interact with N [159].
5’ M mRNA
3’
AUG
AUG
AUG
AUG
AUG
Gn Gc
14k:
NSm2
Gc 78k: NSm1
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NSs protein
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3’ 5’
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Figure 2. (A) Schematic representation of the Rift Valley fever virus genome. The antigenomic sense RNA
and the encoded open reading frames (blue box) are represented. For the ambisense S segment, the genome
and its open reading frame are represented (below). (B) Schematic diagram of the mRNA transcribed from
the segment M of Rift Valley fever virus. (A color version of this ﬁgure is available online at
www.vetres.org.)
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in evasion of the innate immune response
2.3.1. The role of NSs in virulence
Remaining undetermined for many years,
NSs has been identiﬁed as a major factor of vir-
ulence, primarily characterized as an interferon
antagonist. The molecular mechanisms sustain-
ing this phenomenon involve several cellular
proteins interacting with NSs. One of them,
SAP30 belongs to the Sin3A/NCoR/HDAC
repressor complexes which intervene in gene
transcription regulation. Moreover, it was
shown that SAP30 interacts directly with
YY1, a transcription factor involved in the reg-
ulation of expression of numerous genes,
including IFN-ß [151]. Through a series of
co-immunoprecipitation confocal microscopy
and chromatin immunoprecipitations, it was
demonstrated that NSs, SAP30, YY1, HDAC3
and Sin3A-associated corepressor factors are
recruited on the IFN-ß promoter, excluding
CBP (a coactivator known as CREB binding
protein) loading and preventing histone acetyla-
tion and transcriptional activation. To ascertain
the role of NSs interacting with SAP30 in this
mechanism, a recombinant ZH548 RVFV, con-
taining the speciﬁc domain of NSs required for
the interaction with SAP30, was produced by
reverse genetics. In contrast with the virulent
ZH548 RVFV, this mutant, ZH548-NSsD210-
230, was able to induce IFN-ß expression and
was avirulent in the mouse model.
Efforts made during the last few years to
investigate the role of NSs led to the concept
that it is a multifunctional protein, enabling
RVFV to evade the host antiviral response. A
strategy to circumvent the host response relies
on the interaction of the p44 subunit with the
TFIIH basal transcription factor, which is
sequestered by the NSs ﬁlamentous structure
so characteristic of RVFV infection [50, 150].
As a consequence TFIIH cannot assemble and
its concentration drops rapidly, explaining the
drastically reduced transcriptional activity of
cells infected with RVFVexpressing NSs. Inter-
estingly the two functions of NSs complement
each other: ﬁrst, the speciﬁc inhibition of
IFN-ß gene transcription is implemented as
early as 3–4 h post-infection (p.i.) a time at
which IFN-ß would normally be synthesized.
Later during the replication cycle, at a relatively
late time (after 8 h p.i.), a second mechanism
mediated through the interaction of NSs and
TFIIH takes place to inhibit the general tran-
scription of the infected cells.
The RVFV NSs protein is unique among
bunyaviruses as it forms a ﬁlamentous structure
in the nucleus, which is unexpected for a virus
replicating in the cytoplasm [248, 250]. Investi-
gations into the formation of the NSs ﬁlament
showed that cellular DNA is predominantly
excluded from NSs ﬁlaments except for some
speciﬁc DNA regions of the host genome such
as clusters of a pericentromeric gamma-satellite
sequence where NSs interacts with DNA [167].
Targeting of these sequences by NSs was corre-
lated with the induction of chromosome cohe-
sion and segregation defects in RVFV-infected
murine and ovine cells. Such phenomena may
be responsible for the foetal deformities and
abortions observed in infected animals, in addi-
tion to the necrosis of the placentome.
Very recently, a novel function of NSs was
described simultaneously by Ikegami et al.
[127, 128] and Habjan et al. [109]: NSs pro-
motes post transcriptional downregulation of
dsRNA-dependent protein kinase (PKR) and
therefore prevents phosphorylation of eIF2a
(eukaryotic initiation factor 2 alpha), phosphor-
ylated eIF2a being known to lead to suppres-
sion of host and viral translation. Virulent
RVFV was largely resistant to the antiviral
action of PKR because NSs triggers the speciﬁc
degradation of PKR via the proteasome.
Together with the data showing that NSs sup-
presses cellular transcription, these studies on
the downregulation of PKR highlight different
strategies of NSs to prevent the innate antiviral
host responses.
It was also observed that this activity is spe-
ciﬁc to RVFV NSs but not shared with other
phleboviruses like sandﬂy fever Sicilian virus
or the orthobunyavirus, LaCrosse virus [109].
This conclusion was based on the production
of a recombinant ZH548 RVFV in which the
NSs sequence was replaced by the heterologous
NSs from the phlebovirus or the orthobunyavi-
rus. One should note that, in contrast with the
Rift Valley fever virus Vet. Res. (2010) 41:61
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activity of NSs is conserved among orthobuny-
aviruses and phleboviruses [76].
Altogether, it appears that NSs has multiple
functions to counteract the host cell interferon
response, either at the transcriptional or at the
translational levels by degrading PKR, which
in turn facilitates translation of the viral
products [127].
2.3.2. The role of the NSm protein
as a suppressor of virus-induced apoptosis
To determine the biological function of
NSm1 and NSm2, an M segment-deletion
mutant arMP12-del 21-384 was produced in
which the ﬁrst 3 initiating AUG were deleted.
This virus was unable to synthesize the two
nonstructural NSm proteins. Although its
growth was similar to that of the parental virus
arMP12, it induced extensive cell death and
produced larger plaques than the parent [287].
Further analyses indicated that the deletion
mutant triggered apoptosis through the caspase
3, 8 and 9 pathway, thus revealing that NSm
has an anti-apoptotic function and contributes
to pathogenesis. Interestingly, a study on Magu-
ari virus showed that the NSm protein of this
orthobunyavirus, which has no sequence
homology with the NSm protein of phlebovi-
r u s e so rc o m m o nc o d i n gs t r a t e g y[ 148, 202],
is not essential for growth in cultured cells
[225]. It is not yet known if these NSm proteins
from two distantly related viruses from distinct
genera (Orthobunyavirus and Phlebovirus)
share the same anti-apoptotic function. How-
ever, in this case, the same evolutionary path-
way could have occurred to conserve the
functions of both NSm and NSs among genera.
3. MOLECULAR EPIDEMIOLOGY
3.1. Inﬂuence of widespread virus movement,
reassortment and introduction across
natural barriers on RVFV genomics
The evolutionary history of RVFV is com-
plex and has been inﬂuenced greatly by dra-
matic changes to the environment throughout
Africa in the past approximately 150 years.
Over that time, RVFV gene ﬂow has been inﬂu-
enced on multiple levels ranging from the mac-
roscopic (i.e., geographic dispersal) to the
molecular (i.e., reassortment events) [14, 19,
21, 231–234, 239, 288]. Overall, the virus can
be subdivided into at least 7 major genetic lin-
eages (Fig. 3). While no exclusive correlation
of virus genotype and geographic location can
be observed, representatives from one area do
tend to cluster together within each lineage
[19]. However, virus strains with distant origins
can be found within each of the 7 main
lineages, which provide strong evidence of
widespread dispersal and movement of RVFV
genotypes throughout Africa. Striking examples
of the magnitude of this long distance transloca-
tion can be found by the monophyletic linkage
of isolates from regions as distant as Egypt,
Madagascar and Zimbabwe or Kenya, Maurita-
nia, Burkina Faso, Zimbabwe and South Africa
(Fig. 3).
There have been at least three separate intro-
ductions of RVFVacrosssigniﬁcant natural geo-
graphic barriers. The large 1977–1979 Egyptian
‘‘virgin-soil’’ outbreak marked the ﬁrst time the
virus was recognized north of the Sahara desert
andwasassociatedtemporallywithconstruction
of the Aswan High Dam along the Nile river
[133, 183]. Later, the virus was isolated for the
ﬁrst time outside of continental Africa in 1979
across the Indian Ocean in Madagascar where
the virus is now endemic [194–196]. More
recentlyin2000,theviruswasintroducedacross
the Red Sea into Saudi Arabia and Yemen and
precipitated outbreaks among livestock and
humans [10]. In each of these examples, ﬁrm
phylogenetic linkages were established between
RVFV collected during each outbreak and virus
strains circulatingafew yearsearlierwithincon-
tinental Africa [19, 234, 239]. The Arabian Pen-
insula introduction in 2000 is particularly
worrisome, as it appears from the genomic data
that the origins of this ‘‘virgin-soil’’ outbreak
were closely linked to the large 1997–1998 east
African epidemic/epizootic (Fig. 3)[ 19, 239].
After introduction, the virus likely circulated
below the threshold of detection by livestock
and public health authorities until favorable
climatic conditions in 2000 provided an
Vet. Res. (2010) 41:61 M. Pe ´pin et al.
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Figure 3. Rift Valley fever virus M segment maximum a posteriori clade credibility tree, MCMC chain
length 9.0 · 10
7 steps, 2.25 · 10
6 steps (25%) removed as burn-in. Posterior support values (highest
posterior density, HPD) are indicated as integers (i.e., 100% support = 1.0) above each node respectively.
The calculated mean times to the most recent common ancestor (TMRCA) are indicated below each
respective node and are enumerated as years before the collection date of the last outbreak specimen (May,
2007). The 2006–2007 Kenyan outbreak specimen M segment reassortant (strain #0608) is indicated by an
asterisk. Adapted from [21]. (A color version of this ﬁgure is available online at www.vetres.org.)
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that RVFVhas crossedseveralsigniﬁcant physi-
cal barriers with impunity in the past and the
potential exists for further introductions, espe-
cially given ongoing increases in the global
movementofhumans,livestockandmosquitoes.
Genomic rearrangement via RNA segment
reassortment or homologous recombination are
both potent mechanisms to promote genetic
diversity and can allow for the emergence of
novel RVFV strains. The reassortment of RNA
genome segments among viruses of the family
Bunyaviridae has been reported frequently in
both in vitro and in vivo studies [15, 23, 28, 34,
102]. Reassortment among RVFV strains has
also been well documented [19, 21, 231, 234].
However in sharp contrast, no evidence of
homologous recombination among RVFV has
been reported [19]. Potential reassortant events
have been identiﬁed involving each of the three
RVFgenomesegments(i.e.,Ssegment:Lineage
B viruses, M segment: Kenya 2006–2007 strain
#0608, L segment: CAR strain 73HB1230)
[21, 234]. The impact of these reassortment
events on RVFV replication, ﬁtness and, most
importantly, host virulence is not fully known
and requires further detailed study.
3.2. Genomic diversity and molecular
evolutionary rate
Ak e yf e a t u r eo fR V F Vg e n o m i c si st h er e l -
atively low genetic diversity: approximately 4%
and 1% at the nucleotide and protein coding
levels, respectively [19, 21, 231, 239]. This
low diversity contrasts sharply with other buny-
aviruses, including the tick-borne Crimean
Congo haemorrhagic fever virus which was
found to have approximately 32% diversity at
the nucleotide level [31, 59]. The low genomic
diversity of RVFV suggests that the virus either
has a very low tolerance for mutation within its
genome (i.e., an inherently slow molecular
clock, or a ‘‘double-ﬁlter’’ selection mecha-
nism) or alternatively that the extant viruses col-
lectively identiﬁed today as RVFV have a
relatively recent common ancestor. The molec-
ular evolutionary rates (measured as nucleotide
substitutions per site per year) were recently
calculated for 60 complete genomes using
a relaxed clock Bayesian algorithm [21, 67,
68]. The mean evolutionary rates and 95%
highest posterior probability distributions
(shown in parentheses), were 3.9 · 10
 4 (2.4–
5.5 · 10
 4), 3.6 · 10
 4 (2.6–4.6 · 10
 4)a n d
2.8 · 10
 4 (1.8–3.9 · 10
 4) nucleotide substi-
tutions/site/year for the S, M and L segments,
respectively, and were comparable with other
arthropod-borne or mammalian host-restricted
single-stranded negative-sense RNA viruses
[21, 65, 132].
3.3. Recent ancestry and the inﬂuence
of environmental change
Using the known date of collection for each
virus specimen, the molecular evolutionary rate
and the overall genomic diversity, it was possi-
ble to estimate the number of years prior to the
present that the progenitor of the known RVFV
was in circulation [67, 68]. Complete genome
data from 60 naturally occurring RVFV speci-
mens [19] revealed that the time to the most
recent common ancestor (TMRCA) occurred
in the recent past, with mean values of the
TMRCA coalescing towards 120–130 years
before the present, i.e., approximately 1880–
1890. Such a contemporary origin was surpris-
ing, but is broadly consistent with the earliest
case reports from Kenya in the early 1900s of
a disease resembling RVF among animals
[253]. During that time, major ecological
changes were occurring in eastern and southern
Africa, with the establishment of colonial agri-
culture systems and the importation of large
numbers of highly susceptible European breed
livestock [110, 163].
Taken together, the TMRCA and veterinary
case reports support a hypothesis that at some
time between 1850 and 1910, a previously
unrecognized arbovirus ancestor of what we
now know as RVFV exploited a newly formed
ecological niche created by the sudden appear-
ance of large concentrations of susceptible live-
stock. Since that time, the virus has
subsequently established itself throughout large
portions of eastern, western and southern
Africa. The strong phylogenetic linkage of virus
strains from distant locations suggests that, dur-
ing the intervening years, the movement of
Vet. Res. (2010) 41:61 M. Pe ´pin et al.
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mosquitoes could have allowed the spread
of RVFV throughout continental Africa,
Madagascar and the Arabian Peninsula.
3.4. Insights into RVFV molecular epidemiology
from the east African 2006–2007 outbreak
The large 2006–2007 epizootic/epidemic
that occurred in Somalia, Kenya and Tanzania
provided the ﬁrst opportunity to conduct a
detailed examination of RVFV molecular epide-
miology during an outbreak [206]. During the
epidemic period, a total of 1 062 human cases
and 315 fatalities were reported throughout
the region, along with dramatic losses to live-
stock production [285]. As part of the outbreak
response, approximately 3 250 animals from
Kenya (including cattle, sheep, goats, camels
and various wildlife species) were tested for
RVFV [21]. Of these, 289 (9.2%, primarily
sheep, cattle, goats and African buffalo) were
found to be acutely infected with RVFV by
RT-PCR, antigen detection and IgM ELISA.
The complete sequences of the S, M and/or L
genome segments were obtained from a total
of 31 virus specimens representing all affected
regions of Kenya and spanning the entire
known outbreak time period (December 2006
until May 2007).
All 31 virus specimens were monophyletic
with a virus specimen (strain 0523) collected
during the previous 1997–1998 east African
outbreak and clustered with a larger east Afri-
can lineage of RVFV (Fig. 3). This lineage
has been present in Kenya since at least the
early 1980s, as evidenced by monophyletic
grouping of the S, M and L segments (with
100% support) with a RVFV (strain 21445) col-
lected in 1983. Among the 2006–2007 viruses
analyzed, two separate and highly supported
sub-lineages (Kenya-1 and Kenya-2) were
observed (Fig. 3). In contrast with more limited
data from previous outbreaks, there was
increased genomic diversity ( 1.6% at the
nucleotide level) relative to that observed
among RVFV collected during the Egyptian
1977–1979 (0.3%) and Mauritanian 1987
(0.3%) outbreaks (Tab. I). This ﬁnding was
unexpected and may reﬂect differences in the
ecological/epidemiological factors that initiated
each outbreak. The 2006–2007 Kenya outbreak
occurred in a known endemic area, whereas the
Egyptian and Mauritanian outbreaks likely
resulted from limited or single introductions
of RVFVonto ‘‘virgin-soil’’.
While the shared evolutionary history of the
1997–1998 and 2006–2007 outbreak viruses
was apparently based on phylogeny, the
TMRCA of the Kenya-1 and Kenya-2 lineages
detected in 2006–2007 was found to be shortly
before or during the previous 1997–1998 out-
break (Fig. 3). Surprisingly, further population
genetics-based approaches revealed that the
recent evolutionary history of the Kenya-1 and
Kenya-2 lineages differed. Both lineages were
more closely related to the 1997–1998 RVFV
prototype than to each other, indicating ongoing
and separate evolutionary patterns since the
previous outbreak (Fig. 4). More detailed
population genetics analyses revealed that the
Kenya-1 lineage viruses had recently undergone
demographic or spatial expansion, whereas the
Kenya-2 lineage viruses had likely not (Fig. 4)
[21]. Interestingly, the timing of the Kenya-1
expansioneventwascalculatedtohaveoccurred
afew(2.1–3.7)yearspriortothedetectionofthe
2006–2007 outbreak event (Fig. 3). These pop-
ulation genetics-based estimates were found to
correlate closely with data from climate models
that incorporate normalized difference vegeta-
tion imaging that indicated the potential for
enhanced RVFV activity risk during that time
period
2. Taken together, these results suggest
that an undetected and signiﬁcant demographic
and spatial expansion of the Kenya-1 lineage
occurred during the intervening years between
the 1997–1998 and 2006–2007 outbreaks.
These differing evolutionary patterns are consis-
tent with potentially important biological differ-
ences in reproductive ﬁtness existing between
local subpopulations of virus within the natural
environment.
During this outbreak, human and veterinary
epidemiologic data revealed an apparent tempo-
ral course of virus activity shifting from the
north-east border of Kenya towards the south-
west and extending into Tanzania. At that time,
2 ftp://rvf:geis@pengimms.gsfc.nasa.gov
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Figure 4. Minimum spanning networks (MSN) visually describing discrete genetic distance between
unique haplotypes of the RVFV M genome segment within the greater east African lineage. Each node
represents one nucleotide difference between extant (open circle) or inferred (black ﬁlled circle) haplotypes.
Proportionally larger open circles or squares represent the relative number of extant haplotypes represented
in the network. Generally, squares denote the predicted progenitor haplotype for each lineage, whereas
circles indicate progeny haplotypes. Note the greater distance as measured in nucleotide changes (steps)
between the Kenya-1 and Kenya-2 lineages than with the prototype Kenyan 1997–1998 RVFV strain. Also
note the star-like phylogeny of the Kenya-1 lineage indicating the potential for increases in virus population
size or geographic range. An asterisk indicates the relative position of the putative M segment reassortant
virus (strain #0608). Adapted from [21].
Table I. Comparison of M segment nucleotide (NT) diversity among RVFV collected during enzootic/
endemic and epizootic/epidemic time periods.
Country of origin Date of collection Virus activity % nt difference
Zimbabwe 1970–1978 Endemic 4.7
Central African Republic 1973–1974 Endemic 1.8
Egypt 1977–1979 Epidemic 0.3
Mauritania 1987 Epidemic 0.3
Kenya 2006–2007 Epidemic 1.6
Vet. Res. (2010) 41:61 M. Pe ´pin et al.
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tial virus emergence in the north-east followed
by direct ‘‘wave-like’’ spread of the virus via
livestock or mosquito translocation or, rather,
due to changes in rainfall patterns throughout
the region, allowing for the eruption of local
enzootic foci of virus activity. Among the 31
virus specimens analyzed, no signiﬁcant evi-
dence could be detected of a correlation
between genotype, time of collection, or geo-
graphic origin [21]. This suggests that changes
in rainfall patterns were more likely responsible
for the apparent shift in activity rather than
‘‘wave-like’’ spread throughout the region.
The 2006–2007 data provide a unique basis
forunderstandingthecomplexinterplaybetween
theenvironment,virusandsusceptiblehoststhat
allowsfortheestablishmentofRVFVendemicity
andtoprecipitateoutbreaks.Itisclearthatwithin
the Kenyan ecosystem particular virus lineages
can contribute to multiple periodic outbreak
events over relatively long time periods.
Although widespread and explosive RVFVout-
breaks are hallmarks of the virus life cycle, the
importance of a cryptic enzootic transmission
cycle cannot be overstated and requires further
study.
4. PATHOGENESIS AND IMMUNE
RESPONSES
4.1. Natural infection in animals and humans
The natural disease has been well described
in susceptible animals and particularly in rumi-
nants since the ﬁrst identiﬁcation of RVFV in
the Rift Valley of Kenya during an epizootic
in 1930 [51, 52]. Numerous and well docu-
mented descriptions of the symptoms in natu-
rally-infected animals have been recorded [42,
43, 253] and, consequently, detailed descrip-
tions of the natural disease have not been con-
ducted during more recent epizootics. Instead,
the most recent descriptions of RVF epizootics
have focused on the analytical and predictive
epidemiology of the disease [38–40, 168, 169,
272]. A clear distinction can be made regarding
the susceptibility to, and progression of the dis-
ease in young animals when compared with
adults. The basis for these observed differences
has not received clear explanation but might be
driven by age-related susceptibility of the pri-
mary target cells of the virus that allows for
more intense viral replication during early
infection. Alternatively, differences in the
underlying mechanisms of innate immunity that
are stimulated by infection, as has been demon-
strated with other infectious pathogens and dis-
ease models, may exacerbate susceptibility of
young animals to RVFV [294].
The classical hallmark of RVF epizootics is
the large number of near simultaneous abortions
among pregnant ruminants, regardless of the
stage of pregnancy. These massive abortion
events have been referred to as ‘‘abortion
storms’’ and allow for the differentiation of
RVF from many of the other common infec-
tious causes of abortion in ruminants such as:
Qf e v e r( Coxiella burnettii), chlamydiosis,
salmonellosis, listeriosis or toxoplasmosis. In
non-endemic countries, an active surveillance
strategy employing the use of sentinel herds is
cost prohibitive. However, robust passive sur-
veillance-based systems that rely on the detec-
tion and rapid reporting of signiﬁcant abortion
events to national authorities (e.g., > 20% of
pregnant animals in a herd suddenly aborting
with accompanying signs of jaundice among
survivors) could provide a cost effective means
to detect the emergence of this signiﬁcant veter-
inary and human health threat.
RVFV infection of animals can occur by the
bite of an infected mosquito or by direct contact
with infected animal tissues, bodily ﬂuids and
fomites, particularly if associated with abor-
tions. Aborted foetal materials and placental
membranes contain large numbers of virus par-
ticles which can either contaminate the local
environment directly or infect animals in close
contact. The RVFV may persist for relatively
long periods in the environment as has been
demonstrated during in vitro experiments [9,
49, 257].
The relative importance of each mode of
transmission varies according to the stage of
the epizootic: in the ﬁrst stage, the bites of in-
fected mosquitoes are the predominant mode
of transmission whereas direct contact of ani-
mals with infected tissues (foetal or otherwise)
Rift Valley fever virus Vet. Res. (2010) 41:61
(page number not for citation purpose) Page 13 of 40may become predominant during the ampliﬁca-
tion stage of the epizootic [191]. The relative
importance of each mode of transmission still
remains a bit controversial as some authors
argue that the bites of infected mosquitoes con-
stitute the main means of transmission of the
virus, whatever the circumstances and even dur-
ing a large outbreak [22, 25]. Exposure to
infected tissues or bodily ﬂuids constitutes the
main route of infection for humans [253].
Transmission via infected mosquitoes remains
important for the dissemination of RVFV
between herds or ﬂocks over short distances
but also allows for the emergence and dissemi-
nation of the disease over longer distances,
throughout a region or a country, but has to
be preceded by the movement of infected ani-
mals [36] or by translocation of infected mos-
quitoes. Mosquito-borne transmission is also
the most important mode during an enzootic
cycle, i.e., without any clear signs of the disease
but with an active circulation of the virus
between susceptible animals.
The mechanisms and epidemiological
importance of virus shedding from mammalian
hosts is also a subject of debate. It is clear that
the infectivity of blood during acute infection is
high, with extremely high titres of virus up to
10
8.5 mouse LD50 p e r0 . 0 2 m Lo fb l o o da t
the peak of viraemia in sheep [173]). Aborted
materials constitute another route of virus trans-
mission, through direct contact with foetal
envelopes, placenta and the foetus. Virus within
these tissues may stay infectious over a period
of a few days as RVFV particles are rather resis-
tant to inactivation when in a protein-rich envi-
ronment. In contrast, other sources of virus like
nasal and lacrymal secretions have been sug-
gested but not conﬁrmed in controlled labora-
tory studies [274, 275]. The shedding of
RVFV into milk has potentially large conse-
quences for public health. The consumption of
raw milk, such as during the small epidemic
in Mayotte [242], is often reported as a potential
risk factor for exposure to the virus. The prob-
ability for presence of the virus in milk during
the viraemic phase has been conﬁrmed experi-
mentally but in later stages of infection, the
presence of virus in milk is questionable
and, if it exists, the viral load would be low
[70, 71]. To date, the presence of RVFV in
the faeces or urine of infected animals has not
been demonstrated, except when contaminated
by frank blood.
In humans, detailed studies of RVFV infec-
tion were completed during several of the more
recent epidemics that occurred in the Arabian
Peninsula and in Africa. These recent outbreaks
have provided an opportunity to examine con-
ﬁrmed RVF cases and investigate associated
disease symptoms more precisely. In the vast
majority of cases, infection with RVFV was
asymptomatic. For the small proportion with
clinical signs, the majority presented with an
inﬂuenza-like syndrome without any severe
sequelae. However, RVFV epidemics can
involve hundreds if not thousands of individu-
als. The manifestation of severe RVF disease
in humans is variable. Humans may develop a
wide range of clinical signs including hepatitis,
retinitis, delayed-onset encephalitis and, in the
most severe cases, haemorrhagic disease. The
overall case fatality ratio is estimated to be
between 0.5% and 2%. Human cases with jaun-
dice, neurological disease, or haemorrhagic
complications are at increased risk of fatality
[149, 164]. A summary of the frequency and
clinical characteristics of a RVF epidemic that
occurred in Saudi Arabia in 2000–2001 [11]
in 683 patients [164] can be found in Table II.
It is worthwhile to note that, in contrast to the
massive abortion storms and extremely high
fatality observed among young ruminant ani-
mals during epizootics, human children, preg-
nant women and neonatal infants seem to
have been spared the disease. During the
2000–2001 RVF outbreak in the Arabian Penin-
sula, no child under the age of 10 years old was
conﬁrmed to have died as a result of RVFV
infection. The underlying difference in suscepti-
bility of young and pregnant animals with that
observed in humans requires further study and
raises an important question: are the dramatic
differences in lethality the result of a lack of
contact of children with infected mosquitoes
or infected animals or are there true differences
in susceptibility between young animals and
young children?
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Animal models of RVFV infection are
important for reproducing natural infection in
a controlled manner. These models have con-
cerned various target and non-target animal
species: ruminants (sheep, goats and cattle),
laboratory animals (mice, rats and hamsters)
and non human primates [22].
The incubation period following infection,
ranges from a few hours to a few days and is
dependent on multiple factors, including: the
inoculation dose, the virus strain, the route of
inoculation, the age of each animal and the ani-
mal species tested. When clinical signs do
appear, there is a marked febrile response that
m a yb ev e r yh i g h( >4 2 C) and may last for
3d a y s( r a n g i n gf r o m0t o5d a y s ) .D u r i n ga c u t e
infection, the viraemic phase is another almost
constant feature of experimental RVFV infec-
tion, but may vary in intensity and duration
according to the inoculated dose, the virus
strain and the degree of natural susceptibility
of the infected animals. Depending on the
host’s innate susceptibility or resistance, exper-
imental infections often result in three scenarios
[41, 56, 189, 198, 259, 289]:
– Scenario 1: Severe acute lethal infection. In
this scenario the viraemia is uncontrolled,
remains high and the infected animal dies
rapidly. A clear relationship has been dem-
onstrated between the viral load in blood
(as assessed by real time RT-PCR or
LAMP) – for loop-mediated isothermal
ampliﬁcation-PCR; see Section 6: ‘‘Old
and new diagnostic tools for RVF’’ – and
the ﬁnal prognosis and outcome of infec-
tion [18, 152, 210, 223] in humans and in
livestock. In these studies, humans with a
high virus load at the time of presentation
at hospital were found to be signiﬁcantly
associated with fatal outcome.
– Scenario 2: Mild to asymptomatic infec-
tion. The viraemia decreases rapidly, if
present at all, and the infected animals
recover their initial status without any long
term sequelae.
– Scenario 3: Delayed onset complications
of infection. After the ﬁrst phase with
fever and viraemia, a second phase can
occur with an additional febrile phase
and viraemia that may be the result of sec-
ondary dissemination of virus into other
organs, particularly in the central nervous
system, after crossing the blood–brain bar-
rier, and in the retina, leading to a delayed
onset of symptoms that are often associ-
ated with severe, long term consequences,
including blindness, ataxia and potential
fatalities.
The patterns observed during experimental
infection of animals are similar to those
reported for natural infections of animals and
humans. In both natural and experimental infec-
tions, consistent elevations of liver enzymes
and decreases in total leukocyte counts are asso-
ciated with severe disease.
In both animals and humans, the primary site
of RVFV-induced lesions is the liver. This ﬁnd-
ing is consistent among severe cases and has
Table II. Clinical features of 683 patients with
laboratory-conﬁrmed RVF in Saudi Arabia in
2000–2001 (adapted from [164]).
Variable n
a/N
b (%)
Fever 499/539 (92.6)
Nausea 315/530 (59.4)
Vomiting 280/532 (52.6)
Abdominal pain 202/532 (38.0)
Diarrhea 118/530 (22.1)
Jaundice 96/530 (18.1)
CNS manifestations 81/475 (17.1)
(confusion, lethargy,
disorientation, vertigo, coma,
tremor, convulsions, ...)
Haemorrhagic manifestations 35/494 (7.1)
(haematemesis, petechiae, bleeding,
purpura, gingival bleeding,
epistaxis, ...)
Ocular complications
(vision loss, scotomas, ...)
10/683 (1.5)
Deaths 95/683 (13.9)
a n = Number of patients with symptom.
b N = Number of patients under active observation.
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examination of tissues of experimentally-
infected sheep [44, 45]. The rapid onset of
severe hepatic damage, particularly in rumi-
nants, may explain many of the early clinical
signs associated with severe RVF disease.
Although RVFV is primarily hepatotropic, dur-
ing severe infections the virus can be found in
virtually all tissues and cell types [78], indicat-
ing that the as yet undiscovered cellular recep-
tor is likely to be ubiquitous. In the absence
of an efﬁcient innate response (due to the mech-
anisms used by the virus for blocking the pro-
duction of host-cell antiviral proteins induced
by type I interferons via the NSs gene product;
see previous Subsection 2.3: ‘‘The nonstructural
proteins and their role in evasion of the innate
immune response’’), the virus causes marked
cytopathic effect very rapidly following infec-
tion of the primary target cells, leading to mul-
tifocal to coalescing zones of hepatic necrosis
with inﬂammatory inﬁltrates of immune effec-
tor cells. The ﬁnding of widespread hepatic
necrosis is a classic hallmark of severe RVFV
disease both in experimental [43, 44] and natu-
ral infections [78].
The primary tropism for the liver, after the
presumed initial uptake of virions by immune
system sentinel cells, may be altered when an
aerosol route of exposure is employed. While
not a typical route of exposure, this mode of
infection has been described among slaughter-
house and laboratory workers [1, 33, 246]. In
mice experimentally infected after inhalation
of infectious aerosols, the lungs became the pri-
mary site of replication without any clear signs
of pneumonia. However, after 48 h following
experimental aerosol infection, the virus was
isolated from the livers of infected mice that
died as a result of a fulminant hepatitis associ-
ated, as already described, with a massive hepa-
tic necrosis [29].
While infection via the oral mucosal surfaces
has been documented [71, 72], attempts to
infect lambs, kittens and puppies with RVFV-
contaminated milk were not successful [141].
Infection of lambs via the intestinal tract by
ingestion of RVFV-containing gelatin capsules
was also unsuccessful but is a possible route
of infection. However, the acidity of the stom-
ach lumen is deleterious for RVFV, which is
very susceptible to inactivation in solutions
with a pH of less than 6.8 [143, 186].
Some animal models, particularly inbred
strains of rats, have very striking differences
in susceptibility to RVFV infection [4, 221].
These differences are not simply limited to dif-
ferences between lineages of inbred strains but
also depend on the commercial breeding source
used in these studies [228]. As an example,
Wistar-Furth (WF) rats were found to be very
susceptible to experimental RVFV infection
and Lewis (LEW) rats were resistant in one lab-
oratory [6, 8, 221]; in another experiment using
rats from an European breeding colony (mol),
LEW/mol rats developed acute hepatitis and
died after infection, whereas WF/mol rats sur-
vived the infection [228]. Genetic differences
in susceptibility to RVFV infection, such as
those observed in experimental infections of
inbred rats, may explain in part the conﬂicting
susceptibilities seen among different breeds of
sheep under ﬁeld conditions [80], although
these results were not reproduced during con-
trolled experimental infections [211, 259]). Pre-
vious experiments with back crosses of inbred
rat strains suggest that the number of genes
governing these susceptibility differences in
the rat may be low [220] and suggests that it
may be possible to select for resistant domestic
animals through controlled breeding programs.
4.3. Immune responses
A robust innate immune response is critical
for control of the initial phase of virus dissem-
ination and eventual animal survival. A vigor-
ous adaptive immune response is developed
rapidly following infection, with the production
of detectable neutralizing antibodies from the
4th–8th day after infection [117, 188, 193,
216]. These antibodies, which are primarily
directed against the viral glycoproteins, Gn
and Gc, are also accompanied by the production
of IgM and IgG antibodies raised against the
nucleoprotein, N, and the nonstructural protein,
NSs [171]. The N nucleoprotein is the major
immunogen in bunyavirus infection [79, 130]
and represents the complement ﬁxing antigen.
While the titers of antibodies against the N
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antibodies against the NSs protein is typically
rather lower. The measurement of anti-N and
anti-NSs antibodies can allow a DIVA (differ-
entiation of infected and vaccinated animals)
test to be developed as the animals vaccinated
with an inactivated or a recombinant live atten-
uated vaccine such as the candidate clone 13 or
one similar to those reported in Bird et al. [22]
(which contained partial or complete deletions
of the NSs gene [20, 201, 271]) do not produce
antibodiesagainst NSs [171] (see also Section 6:
‘‘Old and new diagnostic tools for RVF’’). The
titration of IgM antibodies is critical for detec-
tion of acute infections and can be coupled with
the results of molecular (RT-PCR) and IgG
detection assays to accurately stage the time
since infection as IgM antibodies do not persist
beyond the 50th day in the majority of cases
after infection [209, 213]. However, important
individual variation in IgM persistence has been
demonstrated in cattle where IgM antibodies
may persist for 5 months, so individual animal
results must be evaluated within this context
[197]. By combining virus isolation in cell cul-
ture or molecular detection of viral RNA with
IgM and IgG antibody assays, it is possible to
determine the stage of infection quite precisely
(see Fig. 5). The neutralizing antibodies are the
key factor for the initial and persistent protec-
tion of infected animals [222] and are, conse-
quently, a good correlate of the protection
induced by vaccines against RVFV: if vacci-
nated animals produce a high level of neu-
tralizing antibodies, they will very likely be
protected against experimental challenge or
subsequent natural viral infection under ﬁeld
conditions [73].
Deep knowledge regarding RVFVimmunol-
ogy is lacking and requires further detailed
studies of both the innate, humoral and cell-
mediated immune pathways.
5. VECTORS OF RVFV
RVFV has the potential to infect a remark-
able array of vectors, including ticks and a vari-
e t yo fﬂ i e s[ 53, 55, 88, 146, 153, 157, 158, 184,
268], unlike the majority of arboviruses which
tend to be adapted to a narrow range of vectors
[35, 60, 137, 166, 180, 187, 279, 283]. The pro-
pensity of the virus to develop signiﬁcant vira-
emia in sheep, goats and cattle and to adapt to
anthropogenic alteration of the environment,
from development of irrigation schemes for
Figure 5. Schematic representation of time course of viraemia and antibody responses against RVFV in
experimentally-infected animals. (A color version of this ﬁgure is available online at www.vetres.org.)
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mosquito vectors) to intensive farming with
livestock, may be responsible for this adaptabil-
ity. Vectors of RVFV can be classiﬁed into
‘‘reservoir/maintenance’’ vectors, including cer-
tain Aedes species (spp.) mosquitoes (Diptera:
Culicidae) associated with freshly ﬂooded tem-
porary [86, 87] or semi-permanent fresh-water
bodies [98], and ‘‘epidemic/amplifying’’ vec-
tors, consisting of Culex spp. associated with
more permanent fresh–water bodies [178].
Tables III and IV list those species from
which RVFV has been isolated in the wild,
w h i c hh a v ea l s ob e e ns h o w nt ob es u s c e p t i b l e
to and capable of transmitting RVFV in the lab-
oratory. The minimum infection rates (MIR),
based on the numbers of isolations per 1 000
adult female mosquitoes, support the epidemio-
logical importance of Aedes (Neomelaniconion)
mcintoshi (Huang, 1987), Aedes (Aedimorphus)
vexans subspecies arabiensis (Patton, 1905),
Aedes (Aedimorphus) dentatus (Theobald,
1904), Culex (Culex) theileri (Theobald, 1903)
and Culex (Culex) poicilipes (Theobald, 1903)
as RVFV vectors. The vector competence index
(VCI) [136] allows for combining infection and
transmission rates into a single statistic for com-
paring the experimental vector competence of
vectors. This statistic illustrates the importance
of the usual RVFV vectors, except for Ae. mcin-
toshi, the most important maintenance vector of
RVFV in east and southern Africa. However,
isolation, infection and transmission rates alone
are not always sufﬁcient to determine vector
capability. Abundance, longevity, distribution
and feeding behaviour are all important facets
of what constitutes a good vector, as are inher-
ent capabilities such as threshold susceptibility
to infective virus. This is illustrated with
Cx. pipiens, the RVFV vector responsible for
the extensive 1977 Egyptian outbreak [115,
182]. Values of the MIR (Tab. III) are consis-
tently low for this species. However, the VCI
range from low to extremely high (Tab. IV)
for the various experiments. A striking feature
of Table IV is the range of IR, TR and VCI
for Cx. pipiens and Culex (Culex) antennatus
(Becker, 1903), the signiﬁcance of which is
not readily obvious. The Egyptian Cx. pipiens
involved in transmission of RVFV is almost
certainly of the variety molestus,a nu n u s u a l l y
anthropophilic, endophilic form of the normally
ornithophilic, exophilic type species. To com-
plicate things further, Culex (Culex) quinquefas-
ciatus (Say, 1823), which is morphologically
similar to Cx. pipiens and behaviourally similar
to Cx. pipiens var. molestus, also occurs in this
area. The presence of all three taxa in Egypt, the
source of the mosquitoes used in the vector
competence experiments, may be responsible
for these disparate results but this has yet to
be demonstrated. Gargan et al. [94] demon-
strated that degree of colonization of experi-
mental Cx. pipiens had a signiﬁcant effect on
infection and transmission rates, with infection
rates increasing (possibly due to artiﬁcial selec-
tion of more susceptible individuals) and trans-
mission rates decreasing on average. Filial (F)
generations of Cx. pipiens in the published
experiments ranged from F2 [177]t oF 67
[261]. The one thing the three members of
Cx. pipiens sensu lato do have in common is
widespread and abundant association with the
settlements and irrigation canals along the
banks of the Nile River and in its delta, in close
association with humans and livestock and ide-
ally situated to act as vectors.
Transmission of RVFV was associated pri-
marily with a limited number of mosquito spe-
cies prior to 1987, even though it had been
isolated from a much wider range of arthro-
pods, including Simulium spp. blackﬂies (Dip-
tera: Simuliidae) [268], Culicoides spp.
midges (Diptera: Ceratopogonidae) [55, 153]
and Amblyomma variegatum ticks (Acari: Ixod-
idae) [88]. Experimental susceptibility and
transmission studies extended the range of
potential vectors to include Phlebotomus spp.
sandﬂies (Diptera: Psychodidae) [64, 263], Rhi-
picephalus appendiculatus ticks [52] and a host
of mosquito species [91, 96, 135, 176, 260,
261, 264]. However, the recognized vectors
responsible for maintenance and ampliﬁcation
of RVFV included members of the subgenera
Neomelaniconion of Aedes and Culex of Culex
[98, 135, 144, 158, 172, 176, 179].
Member species of the mosquito genera,
Anopheles, Eretmapodites, Coquillettidia and
Mansonia have been implicated as vectors after
isolations of RVFV had been obtained from
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the wild.
Species Field isolations
Locality Sample size MIR/1000 References
Ae. (Adm.) dentatus Zimbabwe 1969 23 43.5 [172]
Ae. (Adm.) vexans arabiensis Senegal 1991–1996 42055 0.2 [88]
Saudi Arabia 2000 8091 0.9 [138]
Saudi Arabia 2000 122 8.2 [185]
Ae. (Neo.) circumluteolus South Africa 1955 4657 0.4 [144]
Uganda 1955 1508 0.7 [282]
South Africa 1981* 695 1.4 [134]
Ae. (Neo.) mcintoshi Kenya 1981–1984 59644 0.2 [157]
Kenya 1978–1979 12 83.3 [55]
Zimbabwe 1969 3842 0.5 [172]
South Africa 1974–1975 1315 1.5 [176]
Ae. (Neo.) palpalis grp.** Central African Republic 1969 795 1.3 [63]
Cx. (Cux.) antennatus Nigeria 1967–1970 unrecorded (1)*** [153]
Kenya 1989 250 0 [160]
Kenya 1981–1984 4988 0.6 [157]
Egypt 1977 121 0 [182]
Cx. (Cux.) neavei South Africa 1981 1953 0.5 [179]
Cx. (Cux.) pipiens Egypt 1977–1978 39150 0.03 [115]
Egypt 1977 52629 0.04 [182]
Kenya 1989 4987 0 [157]
South Africa 1970 4833 0 [172]
South Africa 1981 63 0 [179]
Cx. (Cux.) poicilipes Senegal 1998–1999 24327 1.5 [62]
Mauritania 1998–1999 4691 5.8 [62]
Cx. (Cux.) theileri South Africa 1953 unrecorded (2)*** [98]
South Africa 1956 unrecorded (2)*** [176]
Zimbabwe 1969 103 9.7 [172]
South Africa 1970 1398 2.9 [172]
South Africa 1970 144 6.9 [172]
South Africa 1974–1975 12738 0.9 [176]
Cx. (Cux.) tritaeniorhynchus Saudi Arabia 2000 15428 0.4 [138]
Cx. (Cux.) zombaensis South Africa 1981 6621 1.1 [179]
Kenya 1981–1984 2326 0.4 [157]
Zimbabwe 1978 24 0 [254]
Kenya 1989 18828 0.3 [157]
Er. chrysogaster s.l./Er. spp.**** Uganda 1944 1865 1.6 [243]
Er. quinquevittatus South Africa 1971 423 2.4 [172]
Kenya 1981–1984 2660 0 [157]
Oc. (Och.) juppi South Africa 1984 5425 0 [96]
South Africa 1974–1975 2945 1.0 [176]
South Africa 1987 656 0 [135]
* Mostly Ae. circumluteolus with only a few Ae. Luteolateralis.
** Ae. palpalis grp. = jamoti 62%: crassiforceps 21%: carteri 7%: bolensis/palpalis 10%.
*** Number of isolates; undisclosed sample size.
**** Er. chrysogaster s.l. (chrysogaster/semisimplicipes/grahami/intermedius/mahaffyi/haddowi/harperi/gilletti)
75%: inornatus/penicillatus 14%: dracaenae ssp. ferox 11%: leucopus ssp. productus < 1%.
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243, 286]. However, supporting evidence for a
signiﬁcant epidemiological role for these spe-
cies has not emerged; vector competence exper-
iments have shown these mosquitoes to be
susceptible to RVFV but incapable of transmis-
sion or nearly so [53, 91, 174, 175, 177, 178,
245, 264]. Instead, vectors in the subgenus
Aedimorphus of Aedes w e r ef o u n dt ob e
responsible for a large outbreak in West Africa
[87, 293], in particular Ae. vexans ssp. arabien-
sis. This mosquito was also shown to be the
Table IV. Experimental infection rate (IR), transmission rate (TR) and vector competence index (VCI) for
Rift Valley fever virus in mosquito species from which RVFV has been isolated in the wild.
Species Lab experiments
Origins IR/ % (n*) TR/ % (n) References VCI**
Ae. (Adm.) dentatus South Africa 87 (39) 35 (34) [135] 0.31
Ae. (Adm.) vexans arabiensis Saudi Arabia positive (15) 1/1 pool [138]
Ae. (Neo.) circumluteolus South Africa 83 (69) 34 (53) [179] 0.28
South Africa 29 (63) 0 (4) [174]
Kenya 76 (42) 18 (17) [267] 0.13
Ae. (Neo.) mcintoshi South Africa 39 (85) 17 (6) [176] 0.06
Zimbabwe 43 (7) 0 (2) [174]
Kenya 50 (355) 12 (97) [267] 0.06
Ae. (Neo.) palpalis Central Africa Republic 86 (169) 54 (26) [267] 0.46
Cx. (Cux.) antennatus Egypt 84 (25) 38 (16) [91] 0.32
Kenya 60 (135) 60 (5) [267] 0.36
Egypt 92 (48) 7 (30) [264] 0.06
Cx. (Cux.) neavei South Africa 67 (61) 14 (22) [174] 0.09
Cx. (Cux.) pipiens Egypt positive (100) 4/4 pools [115]
Egypt 87 (15) 40 (15) [182] 0.35
Egypt 97 (143) 33 (118) [81] 0.32
Egypt 91 (64) 100 (8) [267] 0.91
Egypt 74 (346) 7 (102) [264] 0.05
Cx. (Cux.) poicilipes South Africa 90 (29) 15 (26) [135] 0.14
Egypt 56 (9) [264]
Cx. (Cux.) theileri South Africa 96 (93) 55 (20) [174] 0.53
South Africa 94 (68) 56 (18) [178] 0.52
South Africa 83 (192) 27 (67) [176] 0.22
Cx. (Cux.) tritaeniorhynchus Saudi Arabia 73 (40) 17 (36) [138] 0.12
Cx. (Cux.) zombaensis South Africa 73 (192) 23 (106) [179] 0.17
Zimbabwe 75 (24) 40 (5) [174] 0.30
Kenya 71 (72) 16 (61) [265] 0.12
Er. chrysogaster/intermedius*** Uganda 78 (92) 4 (92) [245] 0.03
Er. quinquevittatus South Africa 75 (146) 5 (22) [174, 176] 0.03
Oc. (Och.) caballus South Africa 32 (245) 0 (27) [176]
Oc. (Och.) caballus/juppi**** South Africa 33 (3) [98]
Oc. (Och.) juppi South Africa 50 (12) 0 (3) [96]
South Africa 49 (143) 5 (16) [176] 0.03
South Africa 22 (23) 0 (2) [176]
* n = Sample size.
** VCI = IR · TR, with a maximum value of 1.
*** Er. chrysogaster 92%: intermedius 8% based on a limited sample of males.
**** Most likely Oc. juppi as Oc. caballus is rare in the subregion.
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during the emergence of RVFV in 2000 [138,
185]. The epidemic/amplifying vectors in these
new foci were once again members of the Culex
(Culex) subgenus, namely Cx. poicilipes [61,
62]a n dCulex (Culex) tritaeniorhynchus (Giles,
1901) [138].
Theacceptedtransmissionparadigminvolves
survivalofRVFVinmosquitoeggsthroughtran-
sovarial transmission from parous Ae. mcintoshi
and Aedes (Neomelaniconion) circumluteolus
(Theobald,1908)femalestotheirprogenyduring
periods of drought, when the temporary water
bodies dry up completely. These ‘‘ﬂoodwater’’
aedines oviposit on the soils surrounding the
standing water and the eggs require a period of
dehydration before they will hatch, potentially
making them the ideal vehicle for survival of
RVFV over long periods of time [16, 96, 155,
160].Whensuchhabitatsﬂoodafterrainfall,bio-
logical transmission occurs via infected mos-
quito saliva to domestic and wild herbivores of
the family Bovidae (including cattle, buffaloes,
sheep and goats) that may be attracted to the
water supply. The vertebrate hosts are typically
only viraemic for 2–7 days [56, 71, 173, 211],
implyingthatthechronicinfectionoftheinverte-
brate vector is more important for survival of
RVFV from season to season; the vector appar-
ently serves as the reservoir host. Provided the
larval habitats remain ﬂooded for more than
2or3weeks,theﬂoodwaterAedesaresucceeded
by Culex spp., which oviposit in small egg-rafts
onthesurfaceofthewater.Theseeggsareunable
to withstand desiccation. However, the egg rafts
lead to a population explosion of Culex spp.
mosquitoes, which become infected upon feed-
ing on viraemic vertebrate hosts. Whereas the
Table V. Properties of the two existing animal vaccines against Rift Valley fever virus.
Live-attenuated vaccine Inactivated vaccine
Origin/Production – Derived from the Smithburn vaccine
strain (origin = Uganda)
– Attenuated by successive IC
a passage in
newborn mice and in embryonated eggs
(resulting in a neurotropic strain); produced
in cell culture since 1971
– Derived from South African ﬁeld strain
– Inactivation with formaldehyde
– Contains adjuvant
Advantages – Needs only one injection
– Long duration of protective immunity
(entire economic life of animals)
– Inexpensive production costs
– No adverse effects
– No contraindications
Limitations – May induce abortions and fœtal
malformations ! major contraindications
for use in pregnant animals
– Transient viraemia
– Possible residual human pathogenicity
– Possible reassortment with
ﬁeld wild–type virus strains
– Need two injections during the
ﬁrst year and booster doses annually
– Short duration of protective immunity
(necessitating annual booster doses)
– Expensive production costs
Recommendations
for vaccine use
– Prefer live vaccine in countries/
regions where the RVF is enzootic
– Vaccinate before the reproductive season
– Prefer inactivated vaccine in countries/
regions newly infected or free but with a
high risk of RVFV introduction
Common properties – Do not allow the differentiation of
vaccinated and naturally-infected
animals (i.e., no « DIVA
b test » available)
– Age of vaccination: > 6 month of age
a IC = Intracranial.
b DIVA test = ‘‘Differentiation of infected and vaccinated animals’’.
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immediatevicinityofthelarvalhabitatsandonly
feedatduskanddawn,themorenocturnalCulex
spp., e.g., Culex (Culex) theileri (Theobald,
1903), are more likely to disperse to ﬁnd verte-
brate hosts to feed on, leading to extensive dis-
semination of virus and the appearance of
epidemics.
Perhaps the single most important habitat
requirement in the ecology of RVFV is a shal-
low depression in the general topography, with
water-saturated soil overlaying a poorly porous
stratum (e.g., leached sands over granitic bed-
rock and calcic soils over clay-beds that pro-
duces standing water after heavy rainfall)
[284]. Such habitats are distributed throughout
the bushveld-savanna mosaic and higher-
altitude grasslands of sub-Saharan Africa, where
they are known colloquially as ‘‘dambos’’ or
‘‘pans’’ [2, 290] and are typically associated
with sedges and grasses. However, suitable hab-
itats are also to be found in shallow depressions
in the ﬂood-plains of rivers when ﬂoodwaters
overﬂow the river-banks, especially in the
coastal plains of eastern and southern Africa,
as well as in the head-waters to rivers [155].
The West African experience differed from
that seen in Kenya, Zambia, Zimbabwe and
South Africa. The Aedes (Aedimorphus) spp.
typicallyovipositinthesmall,temporaryground
pools that occur after localized rains. The region
oneithersideoftheMauritanian/Senegalesebor-
der had not experienced good rainfall or ﬂoods
prior to the 1987 outbreak and the typical vec-
tors,Ae.(Neo.)mcintoshi,Ae.(Neo.) circumlute-
olusandCx.(Cux.)spp.werenotpresentinhigh
numbersduringtheentomologicalinvestigations
[88]. Conditions were more ideally suited to Ae.
(Aedimorphus) spp., exempliﬁed by Ae. vexans,
Ae. ochraceus (Theobald, 1901), Ae. dalzieli
(Theobald, 1910) and Ae. cumminsii (Theobald,
1903)[36].Atthetime,anewdamwallhadbeen
constructedontheSenegalRiver;thesubsequent
ﬂooding of the river banks was thought to have
effected an increase in the vector and livestock
population densities in the immediate vicinity
ofthedam[88].Withtheadventofasecondout-
break of RVFV in the region, investigators dis-
covered a shift in the dominant mosquito
species, namely towards Mansonia uniformis
(Theobald, 1901) and Cx. poicilipes [62].
Mansonia spp. are associated with gently ﬂow-
ing water and oviposit on the underside of the
leaves and on the submerged roots and stems
of African water lilies and water hyacinth (i.e.,
ﬂoating vegetation), while Cx. poicilipes breeds
in reed beds in permanent water bodies [116].
It appears that the establishment of the dam on
the perennial Senegal River was responsible for
the production of Cx. poicilipes in sufﬁcient
numbers to trigger the second, larger outbreak.
The virus responsible for the 2002 RVF out-
breakintheArabianPeninsula [10,203] appears
to have been caused by introduction of the virus
via imported livestock from East Africa [239].
Irrigation for agriculture in the Tihama
regions of Yemen and Saudi Arabia and the
proximity of the Jizan Dam provided ideal
breeding grounds for both Ae. vexans and
Cx. tritaeniorhynchus and grazing of sheep and
goats along the wadis and irrigation systems in
the foothills of the Sarawat Mountains provided
amplifying hosts [138]. The danger of RVFV
spreading into the Near and Middle East and,
eventually, the European Union has been touted
since the 1977 Egyptian outbreak [115] and its
emergenceintheRedSeacoastalplainofYemen
andSaudiArabiawasseenasasigniﬁcantstepin
the northward migration of the virus. However,
RVFVhasyettoescapetheAfrotropicalRegion,
bounded as it is by the Sarawat escarpment and
the arid inland plateau of Saudi Arabia. Never-
theless, it is essential that potential vectors are
identiﬁed in the boundary regionoftheMediter-
ranean and Middle Eastern countries, requiring
surveillance to monitor species composition,
species abundance and vector competence to
determine vector candidates. Much still needs
to be discovered aboutthe biology of the known
as well as the potential vectors, including the
hypothesis of transovarial transmission. Labora-
tory demonstration of transovarial transmission
has been hampered by the difﬁculty of coloniz-
ing ﬂoodwater Aedes mosquitoes. However,
ﬁeld studies have shown infection of both male
and female mosquitoes reared from ﬁeld-
collected larvae [157] and this needs to be
conﬁrmed and investigated under controlled
conditions, especially considering the report
[262]o fCx. pipiens, Ae. mcintoshi and Ae.
Vet. Res. (2010) 41:61 M. Pe ´pin et al.
Page 22 of 40 (page number not for citation purpose)circumluteolus larvae becoming infected after
feeding on RVFV-positive liver from an experi-
mentally inoculated hamster.
6. OLD AND NEW DIAGNOSTIC TOOLS
FOR RVF
There are increasing demands for high-
quality and procedurally safe diagnostic tests
for zoonotic pathogens to ensure the best pro-
tection of human and animal populations and
to facilitate the free international trade of
animals and animal products. The recently
documented spread of RVFV and other vec-
tor-borne zoonotic pathogens beyond their tra-
ditional endemic boundaries has resulted in
increased international demand for validated
diagnostic tools and speciﬁc immunoreagents
for the rapid diagnosis of RVF. This demand
is greatly challenged by the fact that work with
RVFV requires high biocontainment facilities
and, preferably, needs to be carried out by vac-
cinated laboratory staff, but also because the
virus is regarded as a potential bioweapon
agent. For these reasons, the current capacity
for laboratory diagnosis of RVF is restricted
to a limited number of reference laboratories
worldwide. RVFV belongs to the group of
RNA viral haemorrhagic fever (VHF) agents
that includes Ebola, Marburg, Lassa (and other
arena-), Crimean-Congo haemorrhagic fever,
yellow fever, dengue and hanta-viruses. In the
absence of haemorrhagic or speciﬁc organ man-
ifestations, infections by VHF viruses are clini-
cally difﬁcult to recognise, with the implication
that deﬁnitive diagnosis depends mainly on reli-
able laboratory tests. RVF may be suspected
when there is a sudden outbreak of febrile ill-
ness with headache and myalgia in humans,
in association with the occurrence of abortions
in domestic ruminants and deaths of young ani-
mals. However, cases of RVF in humans are
sometimes only recognized late after infection
from the occurrence of ocular complications.
Late recognition of RVFV infections typically
occurs when only sporadic cases are diagnosed
during inter-epizootic periods. Haemorrhagic or
encephalitic manifestations might be indicative
of RVFV infection, especially in the rare
instances where residents of other continents
develop the illness following a visit to endemic
areas in Africa. Experiences from the more
recent outbreaks in Africa and the Arabian Pen-
insula appear to indicate that outbreaks of RVF
in livestock are only recognized after diagnosis
of the disease in humans.
Diagnosis of RVF is achieved using various
techniques, including virus isolation [7, 240],
antigen detection [181, 208] and nucleic acid
ampliﬁcation techniques [66, 93, 121]a n db y
detection of speciﬁc antibodies [251]. RVFV
is readily isolated from serum or whole blood
during the febrile stage of the disease as well
as from the liver, spleen and brain of fresh car-
casses/cadavers or aborted foetuses. Isolation of
the virus is achieved in hamsters, infant or adult
mice and in various cell cultures [99, 253].
However, virus isolation procedures are lengthy
and expensive. Delays in diagnosis based on
traditional virus isolation and identiﬁcation
techniques may represent a signiﬁcant problem
for regulatory healthcare authorities faced with
a RVF epidemic, especially in countries outside
its traditional geographical conﬁnes. Hence,
considerable efforts have recently been made
to develop nucleic acid techniques for the rapid
detection and identiﬁcation of RVFV.
Highly sensitive PCR assays for the detec-
tion and quantiﬁcation of RVFV have been
reported, including RT-PCR [93, 121, 235]
and real-time detection PCR (RTD-PCR) based
on TaqMan probe technology [18, 66]. More
recently, real-time reverse-transcription loop-
mediated isothermal ampliﬁcation assays (RT-
LAMP) targeting the large RNA segment were
developed and evaluated for the detection of a
wide spectrum of RVFV isolates and clinical
specimens [152, 223]. The RT-LAMP detection
limit was reported to be 0.065 TCID50 per reac-
tion volume [152]a n d 10 RNA copies per
assay [223], and there was 100% agreement
between the RT-LAMP, TaqMan-based RTD-
PCR and virus isolation results [152]. Similarly,
the assay had a very high diagnostic sensitivity
and speciﬁcity when testing various clinical
specimens from humans and animals that were
naturally infected with the virus during recent
outbreaks of RVF in Africa. The detection of
speciﬁc viral genome targets in positive clinical
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less than 30 min. Apart from high analytical
and diagnostic accuracy and speed of detection,
another important practical advantage of the
LAMP assay is that it utilizes simple and rela-
tively inexpensive equipment which renders it
promising for use in resource-poor settings
and as a portable device during RVF outbreaks
in remote areas [152, 223]. During the 2006
RVF outbreak in Kenya, quantitative real-time
RT-PCR (qRT-PCR) was evaluated to identify
patients with high viraemia, which is associated
with poor prognosis [210]. This was the ﬁrst
report of qRT-PCR being used for case-conﬁr-
mation and for correlation of RVFV-RNA lev-
els, measured by qRT-PCR, with infectious
virus titres. Fatal RVF cases had over 3-fold
higher levels of viral RNA (mean = 8.6 · 10
6
viral RNA copies/mL of serum) and 3-logs
higher infectious virus concentrations
(10
5.2 infectious virus particles/mL of serum)
when compared to non-fatal cases (means of
2.4 · 10
6 viral RNA copies/mL and 10
2.3 infec-
tious virus particles/mL of serum). The ﬁndings
in Kenyan [210] and Saudi Arabian [18]
patients sampled during the 2000 outbreak of
RVF, indicate that qRT-PCR can be used for
the rapid identiﬁcation of patients with high vi-
raemia and poor prognosis, thereby enabling
them to be targeted for special or intensive clin-
ical management.
One has to emphasize, however, that deﬁni-
tive diagnosis or exclusion of RVF, as of any
other suspected VHF case, should not rely on
a single PCR result. The nucleic acid detection
assays should be run in parallel with additional
tests, including detection of type-speciﬁc anti-
bodies to RVFV. In this context it is important
to note that viraemia in RVFV-infected individ-
uals is of very short duration and most infected
patients and adult ruminants undergo subclini-
cal or mild infections; however, IgM and IgG
antibodies are easily demonstrable shortly after
exposure to the virus [213–215]. Furthermore,
most nucleic acid techniques require highly spe-
cialized laboratory equipment, sophisticated
reagents and well trained laboratory personnel,
which conditions may not be available when
outbreaks occur in remote regions and when
rapid diagnosis is necessary.
Viral antigen can be detected rapidly in
blood and other tissues by a variety of immuno-
logical methods, including agar gel immu-
nodiffusion using homogenised tissues and
immunostaining on impression smears or on
cryostat sections of liver, spleen and brain;
these assays allow the speciﬁc identiﬁcation
of the RVFVantigen in infected cells. Histopa-
thological examination of the liver of affected
animals reveals a characteristic cytopathology
[99, 253]. Enzyme-linked immunosorbent
assays (ELISA) for the detection of RVFVanti-
gen have also been reported, but most of these
assays were based on reagents that are cumber-
some and expensive to produce and pose a bio-
hazard risk to laboratory personnel [181, 208,
292] .R e c e n t l y ,Z a k ie ta l .[ 292] reported on
immunoﬂuorescence assays which utilize a
pool of mouse IgG monoclonal conjugates
reacting with a combination of virus speciﬁc
antigens (Gs, Gn, N, NSs). Although it was
demonstrated to be highly reliable in detecting
RVFV in patient sera, its use requires tissue
culture ampliﬁcation and handling of live virus.
A number of laboratory infections with RVFV
were recorded under circumstances which indi-
cate the virus to be highly infectious for man
[83, 142, 246]. To address this problem, a sand-
wich ELISA for antigen detection (sAg-ELISA)
based on an entirely safe procedure, including a
set of internal controls based on a recombinant
nucleocapsid protein (recNP) for monitoring of
routine assay performance, which increases its
utility in surveillance and diagnosis in non-
endemic areas, was recently reported [131].
The assay was developed for the detection of
the nucleocapsid protein (NP) of RVFVin spec-
imens that had been inactivated at 56  Cf o r1h
in the presence of 0.5% Tween-20 (v/v) before
testing. The sAg-ELISA has been used to detect
strains of RVFV, that were isolated in geograph-
ically distinct areas of the world over a period
of 53 years, with no cross-reactivity with the
related African phleboviruses or other members
of the family Bunyaviridae. The detection limits
ranged from log1010
2.2 to 10
3.2 TCID50/reaction
volume. Compared to virus isolation results in
sera from RVF patients and experimentally
infected sheep, the sAg-ELISA had 67.7%
and 70% sensitivity, and 97.97% and 100%
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accurate when testing tissues of various organs
from experimentally infected mice and naturally
infected buffalo foetuses. The assay was able to
detect NP antigen in infected culture superna-
tants 12 to 30 h before cytopathic effects were
observed and as early as 8 h after inoculation
with 10
5.8 TCID50/mL of RVFV. This ability
renders the assay suitable for rapid identiﬁca-
tion of the virus when its primary isolation is
attempted in vitro. As a highly speciﬁc, safe
and simple assay, the sAg-ELISA represents a
valuable diagnostic tool for use in less well-
equipped laboratories in Africa and for routine
differential diagnosis of VHF [131].
Serum specimens are commonly used for
RVF diagnosis. Viraemia titers ranging from
10
5.6 to 10
9.0 mouse LD50/mL have been
recorded in domestic ruminants [12, 51, 111,
188, 252], 10
8.6 mouse LD50/mL in humans
[220]a n d1 0
5.4 TCID50/mL in adult African
buffalo [56]. Although viraemia in RVFV-
infected individuals reaches high titres, it is of
short duration, limiting its use for viral detec-
tion systems for RVF outbreak diagnosis.
Therefore, attempts to detect recent RVFV
infection by ELISA should include a combina-
tion of assays which target both viral antigens
and IgM antibody. In contrast, RVFV can per-
sist at high titers for 21 days in ovine brain
and liver and up to 30 days in spleen [289].
The high diagnostic accuracy of the sAg-
ELISA for detecting RVFV in infected tissues,
which usually contain virus concentrations at
least 10- to 100-fold times above the detection
limits determined for the assay [70, 111, 188],
thus renders it ideal for testing specimens from
aborted foetuses and carcasses/cadavers. Sud-
den, high abortion and fatality rates in young
animals are characteristic features of RVF
outbreaks.
Diagnosis of infectious diseases can be made
when serological tests are used in combination
with clinical observations and, epidemiological
history or when seroconversion is demon-
strated. Serodiagnostic techniques are also
widely used to demonstrate freedom from a dis-
ease and in epidemiological investigations. The
classical methods for the detection of antibodies
to RVFV include haemagglutination-inhibition,
complement ﬁxation, indirect immunoﬂuores-
cence and virus neutralization tests (VNT)
[99, 251]. The disadvantages of these tech-
niques include health risks to laboratory person-
nel [142, 177, 246, 268] and restrictions for
their use outside RVF endemic areas. Diagnosis
of recent infection is conﬁrmed by demonstrat-
ing seroconversion or a 4-fold or greater rise in
titre of antibody in paired serum samples, or by
demonstrating IgM antibody activity in an
ELISA [215, 217].
Although regarded as the gold standard, the
VNT is laborious, expensive and requires 5–7
days for completion. It can be performed only
when standardized stocks of live virus and tis-
sue cultures are available. Consequently, it is
rarely used and then only in highly specialized
reference laboratories. However, from the point
of view of using the VNT as a diagnostic dis-
criminator in validation studies, it is important
to note that infection with RVFV induces life-
long neutralizing immunity and that there is
no evidence for the existence of serological sub-
groups or major antigenic variation between
virus isolates of disparate chronologic or geo-
graphic origins [253]. The VNT is highly accu-
rate with little or no cross-neutralization with
other phleboviruses [54, 249, 251, 255]b u t
since it requires live virus, it can only be done
in suitable biocontainment facilities.
Various ELISA formats developed in recent
years for the speciﬁc detection of IgG, IgM or
total antibodies, based on inactivated sucrose-
acetone-extracted antigens derived from tissue
culture or mouse brain were shown to be highly
accurate diagnostic tools in disease surveillance
and control programs, import/export veterinary
certiﬁcation and for monitoring of immune
response in vaccines [32, 213–216, 219]. As
highly accurate, robust and safe tests, they have
the potential to replace traditional diagnostic
methods which pose health risks and necessitate
their use being restricted to high containment
facilities outside RVF-endemic areas. However,
the production of antigen for these assays also
requires bio-containment facilities to limit the
risk of exposure of laboratory personnel to
infection. To address these problems, an indi-
rect ELISA based on the recNP of RVFV has
recently been developed for the detection of
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[79, 130, 217, 218]. The nucleocapsid protein
appears to be highly conserved among mem-
bers of the Bunyaviridae family [97, 165, 237,
269] and antigenic cross-reactivity studies in
animals [54, 249, 252] and the indirect ELISA
based on recNP [217] failed to provide any evi-
dence that other African phleboviruses could
obscure the reliable serodiagnosis of RVF. As
the most abundant and highly immunogenic
viral component in the RVFV virion, NP seems
to be the best choice for the development of
immunoreagents for antigen detection assays.
The fact that a soluble, highly puriﬁed
recombinant RVF NP can be produced easily
in large quantities [130], will allow for less
expensive, fully automated mass-screening of
sera. Research efforts aimed at the development
and validation of a new generation of safe diag-
nostic immunoreagents and assays, for example
ELISA formats based on RVFV recombinant
antigens, are strongly recommended since clon-
ing and expression of RVFV antigens would
avoid the risk of laboratory infections and of
residual virus in the test reagents, making them
safe for routine use in RVF-free areas. How-
ever, it still remains to be proven through
extensive validation studies that recombinant
antigen-based ELISA would have at least the
same diagnostic accuracy in livestock popula-
tions from various geographic regions as
ELISA based on the whole inactivated antigen
of the virus.
7. PREVENTION AND VACCINES
7.1. Existing vaccines
Because of the socio-economical impact of
RVF in Africa, it appeared that vaccines, at least
for veterinary use, were urgently needed. The
ﬁrst vaccine, still in use, was developed by
Smithburn [244] who adapted the Entebbe iso-
late by serial intracerebral inoculation of mice
to attenuate the virulence, a procedure ﬁrst used
by Theiler to produce the yellow fever 17D
vaccine [256]. However, the passaged virus,
called the Smithburn strain, had only partially
lost its virulence: it induced abortions and tera-
togenesis in ewes, cows and goats [24, 139,
154, 253], so that its use is mainly restricted
for use during devastating outbreaks and only
in non-pregnant female animals [13, 253]. To
circumvent these difﬁculties, an inactivated vac-
cine has been produced, allowing the safe vac-
cination of animals, but this vaccine is not as
efﬁcacious as the attenuated vaccines and needs
booster inoculations [12]( Tab. V). After the
Egyptian outbreak in 1977, USAMRIID initi-
ated research to produce a new RVFV vaccine.
The attenuated MP12 was obtained from the
virulent Egyptian strain (ZH548) after random
mutagenesis with 5-ﬂuorouracil during 12 suc-
cessive passages [30]. This virus acquired
mutations in all three segments and had lost
its virulence when tested in mice [236, 270].
Moreover, it was shown to induce a good
immunity in ruminants after experimental inoc-
ulation [190, 192, 193]. However, trials carried
out in South Africa using pregnant ewes
revealed some abortions and teratogenesis dur-
ing the early stages of pregnancy [119]. This
might corroborate data reporting that MP12 still
had some neurovirulence when inoculated into
hamsters, which constitute a very sensitive ani-
mal model [230]. At the present time and in
spite of these data, MP12 is still being devel-
oped as a veterinary and human vaccine. An
alternative candidate based on another RVFV
isolate, Clone 13, was found to be avirulent
d u et oal a r g ed e l e t i o ni nt h eN S sp r o t e i n
[201]. This virus grows to high titers in cell cul-
tures and the deletion in the sequence coding
for the virulence factor made it attractive due
to its inability to revert. Vaccination trials in
sheep, including ewes, and in bovines were car-
ried out. Not only did the virus not provoke any
deleterious effects but the animals elicited a
high antibody response and were protected
against a virulent challenge. Pregnant ewes
were also protected from abortions, which were
observed in the unvaccinated control
animals
3.
3 Dungu B., personal communication.
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While Clone 13 is a natural virus originating
from a mild RVF case, it is now possible to
manipulate the viral genome via reverse genet-
ics to produce similar or different viruses, open-
ing new ways to abrogate its pathogenicity [26].
This has been demonstrated by producing
a rMP12 in which the S segment carries a muta-
tion identical to the one in Clone 13 [124]o rb y
removing the complete NSs sequence from
MP12 or from the otherwise virulent backbone
of the strain ZH501 [20]. In addition, because
NSm plays a role as an anti-apoptotic factor,
a double mutant DNSs/NSm abrogating expres-
sion of both NSs and NSm proteins was created
and shown to be avirulent and to confer com-
plete protection against virulent virus challenge
at dosages up to 1.0 · 10
4 LD50 in the rat
model [20] and in mice
4.
Sub-unit recombinant vaccine candidates
expressing the RVFV glycoproteins have been
described: different vectors such as the lumpy
skin disease virus [276, 277], an alphavirus
[105, 112], a non-replicating adenovirus [114],
or the Newcastle disease virus [145]w e r eu s e d .
Other groups have developed sub-unit vaccines
by expressing the RVFV glycoproteins which
can assemble into ‘‘empty’’ virus-like particles
or VLP [58, 108, 159, 204]. For efﬁcient pro-
duction, recombinant baculoviruses were con-
structed expressing the glycoproteins alone or
in association with N [159]. DNA-based vac-
cine administrated by gene gun has also been
described but required several reimmunizations
[147, 247, 277].
Interestingly, most of the vaccine candidates,
whether live-attenuated virus or sub-unit vac-
cine, have some genes missing when compared
to natural strains circulating in the wild. This
was also the case with Clone 13, its truncated
NSs being degraded rapidly by the proteasome
[271]. This raised the question of vaccine being
able to distinguish infected from vaccinated ani-
mals (DIVA) [20]. An ELISA based on the
detection or non-detection of antibodies against
the NSs protein was developed recently [171].
The test was evaluated using sera from experi-
mentally infected rats and from a small number
of ruminants which had antibody against the
NSs protein, although of low titer. Considering
that NSs is poorly immunogenic, a survey of a
largenumberofanimalsshouldbedonetodeter-
mine if a high proportion of naturally infected
livestock elicits a detectable and long-lasting
immune response against this protein.
8. CONCLUSION
This review demonstrates that RVFV has
become an important subject of interest over
the past three decades and particularly in recent
years, as public health agencies have become
alerted to the possible emergence of this arbovi-
rus in temperate countries. Climate change
[170] and the presence of competent vectors
in currently RVF-free temperate countries
[199, 266, 280] suggests strongly that RVFV
should be included among the most signiﬁcant
emerging viral threats to public and veterinary
health. Recent insights into the virus’ pathogen-
esis, molecular epidemiology, diagnostics and
the increasing number of vaccine trials using
various modern approaches, including reverse
genetics, recombinant vectors, VLP, subunit
vaccines and DNA vaccines [26, 126], have
contributed greatly to our understanding of this
signiﬁcant viral pathogen. Despite these efforts,
safe and efﬁcient vaccines, both for medical and
veterinary use, are still lacking, even though
they are essential for the protection of animal
and human populations and reduction of the
dramatic health impacts of outbreaks, wherever
they may occur. The recent outbreaks in Egypt
and in the Arabian Peninsula have illustrated
the potential of RVFV to spread to previously
unaffected areas, leading to the following
warning, cited by Zabransky (2005) [291]b y
Dr Corrie Brown (University of Georgia,
USA): ‘‘If we get Rift Valley fever [in the USA],
it would make West Nile look like a hiccup.’’
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